Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acalabrutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK known ✓ | Q06187 | 19/20 | 0.97 |
| ▸ | TEC | P42680 | 2/20 | 0.97 |
| ▸ | TXK | P42681 | 2/20 | 0.97 |
| ▸ | BMX | P51813 | 2/20 | 0.97 |
| ▸ | EGFR | P00533 | 1/20 | 0.97 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.97 |
| ▸ | KDR | P35968 | 1/20 | 0.97 |
| ▸ | BLK | P51451 | 1/20 | 0.97 |
| ▸ | JAK3 | P52333 | 1/20 | 0.97 |
| ▸ | ITK | Q08881 | 1/20 | 0.97 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.97 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.97 |
| ▸ | LCK | P06239 | 2/20 | 0.85 |
| ▸ | LYN | P07948 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acalabrutinib SCHEMBL18423041 | 1.00 | BTK (0.97) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL17842601 | 0.98 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL30193365 | 0.98 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL14637370 | 0.98 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL31756796 | 0.98 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL14637368 | 0.98 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL29376537 | 0.98 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL18422160 | 0.96 | BTK (0.96) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL18422158 | 0.96 | BTK (0.96) | BTKTECTXKBMXEGFR | |
| SCHEMBL30468120 | 0.96 | BTK (0.96) | BTKTECTXKBMXEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820777-B2 | Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | ACERTA PHARMA B.V. (NL) | 2023-11-21 | — | — | US | disclosed |
| EP-4209493-A1 | SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE | Acerta Pharma B.V. (NL) | 2023-07-12 | — | — | EP | disclosed |
| US-20220348582-A1 | Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | ACERTA PHARMA B.V. (NL) | 2022-11-03 | — | — | US | disclosed |
| EP-3954690-A1 | SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE | Acerta Pharma B.V. (NL) | 2022-02-16 | — | — | EP | disclosed |
| US-11059829-B2 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate | ACERTA PHARMA B.V. (NL) | 2021-07-13 | — | — | US | disclosed |
| US-20200255437-A1 | Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate | ACERTA PHARMA B.V. (NL) | 2020-08-13 | — | — | US | disclosed |
| US-10640509-B2 | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma | ACERTA PHARMA B.V. (NL) | 2020-05-05 | — | — | US | disclosed |
| EP-3613745-A1 | SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE | Acerta Pharma B.V. (NL) | 2020-02-26 | — | — | EP | disclosed |
| US-20190337949-A1 | Solid Forms and Formulations of Imidazopyrazine Compound | ACERTA PHARMA B.V. (NL) | 2019-11-07 | — | — | US | disclosed |
| US-10167291-B2 | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | ACERTA PHARMA B.V. (NL) | 2019-01-01 | — | — | US | disclosed |
| US-20180208596-A1 | Solid Forms and Formulations of Imidazopyrazine Compound | ACERTA PHARMA B.V. (NL) | 2018-07-26 | — | — | US | disclosed |
| US-9796721-B2 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | ACERTA PHARMA B.V. (NL) | 2017-10-24 | — | — | US | disclosed |
| US-20170029428-A1 | Solid Forms and Formulations of Imidazopyrazine Compound | ACERTA PHARMA B.V. (NL) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640509-B2 | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma | MALT1, BCL6, BCL3 | BTK 200/4885TEC 2879/4885TXK 3528/4885 |
| US-20190337949-A1 | Solid Forms and Formulations of Imidazopyrazine Compound | SLC5A2, IL5, NPY5R | BTK 2274/4885TEC 1675/4885TXK 1649/4885 |
| US-20170029428-A1 | Solid Forms and Formulations of Imidazopyrazine Compound | SLC5A2, IL5, NPY5R | BTK 2274/4885TEC 1675/4885TXK 1649/4885 |
| US-20180208596-A1 | Solid Forms and Formulations of Imidazopyrazine Compound | SLC5A2, IL5, NPY5R | BTK 2274/4885TEC 1675/4885TXK 1649/4885 |
| US-20220348582-A1 | Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | NPY5R, PGA5, ALB | BTK 3073/4885TEC 2951/4885TXK 2383/4885 |
| US-20200255437-A1 | Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate | ALB, TTR, SLC5A2 | BTK 3179/4885TEC 2811/4885TXK 2613/4885 |
| US-10167291-B2 | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | NPY5R, PGA5, ALB | BTK 2571/4885TEC 3134/4885TXK 2398/4885 |
| US-11059829-B2 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate | NPY5R, SLC5A2, PGA5 | BTK 3072/4885TEC 2624/4885TXK 2424/4885 |
| US-11820777-B2 | Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | NPY5R, PGA5, ALB | BTK 2897/4885TEC 2889/4885TXK 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.